X hits on this document

437 views

0 shares

0 downloads

0 comments

116 / 170

7

edema, fractures, and other problems. Insulin has the lowest therapeutic index of

8

virtually any drug on the market and was in 2006 the drug most cited for causing adverse

9

drug events in emergency room visits, frequently due to hypoglycemia or to DKA. It

10

also causes weight gain, which can contribute to heart problems. Obviously, I am very

11

tight with Insulin. I am beyond grateful that it was invented. I am also very much a

12

follower of new Insulins in development and hope that they will, with other drugs, see a

13

reasonable and fair regulatory environment.

2

hypoglycemia. The class is also widely suspected to cause beta cell burnout but given

3

that it is generic it is unlikely, as I understand it, to ever undergo any safety profiling of

4

its own even though it is among the most common medications taken and even though

5

many suspect medicines in this class would never be approved today.

20

Thank you in advance to the committee for considering new alternatives

21

for all adults with diabetes that will improve diabetes management. Currently we seem

22

largely still in a ‘one size fits all’ mode of treating diabetes in the US. The system, for

6

Other classes of widely prescribed diabetes medicines cause weight gain,

15

Advisory Panel why people with diabetes needed more drug classes. You know, as a

16

patient I was really surprised and disappointed by this question. While I want all our

17

patients to be as safe as possible, it’s important to be concerned about patients who aren’t

18

finding success with current treatments. To be satisfied with a range of therapies that has

19

such a gap in treatment success is also surprising and disappointing.

23

the most part, doesn’t support physicians, especially primary care physicians, spending a

24

lot of time with patients. So I hope you will encourage making safe, tolerable,

1

It is also well known that Sulfonylureas cause weight gain and

115

14

Dr. Steven Nissen of the Cleveland Clinic asked at the July 2008 FDA

Scribes, LLC Toll Free 1-800-675-8846 www.scribesllc.com

Document info
Document views437
Page views437
Page last viewedSun Dec 04 12:24:20 UTC 2016
Pages170
Paragraphs7975
Words54271

Comments